Shares of Insmed Inc. (NASDAQ:INSM) were up 3.9% during mid-day trading on Wednesday . The company traded as high as $11.37 and last traded at $11.36, with a volume of 316,874 shares. The stock had previously closed at $10.93.

A number of research firms have weighed in on INSM. Zacks Investment Research downgraded Insmed from a “hold” rating to a “sell” rating in a research report on Thursday, March 31st. HC Wainwright reaffirmed a “buy” rating on shares of Insmed in a research report on Wednesday, June 15th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $24.00 price target on shares of Insmed in a research report on Thursday, June 9th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Insmed in a research report on Sunday, April 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $23.57.

The company’s market capitalization is $702.92 million. The company’s 50 day moving average is $10.53 and its 200-day moving average is $12.04.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.54) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.02. On average, analysts forecast that Insmed Inc. will post ($2.21) earnings per share for the current year.

Several institutional investors recently bought and sold shares of the company. California State Teachers Retirement System raised its position in Insmed by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 113,929 shares of the biopharmaceutical company’s stock worth $2,068,000 after buying an additional 1,804 shares in the last quarter. Jennison Associates LLC raised its position in Insmed by 0.4% in the fourth quarter. Jennison Associates LLC now owns 1,168,760 shares of the biopharmaceutical company’s stock worth $21,213,000 after buying an additional 4,159 shares in the last quarter. Rhumbline Advisers raised its position in Insmed by 7.9% in the fourth quarter. Rhumbline Advisers now owns 64,811 shares of the biopharmaceutical company’s stock worth $1,176,000 after buying an additional 4,735 shares in the last quarter. Finally, ProShare Advisors LLC raised its position in Insmed by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 58,656 shares of the biopharmaceutical company’s stock worth $1,065,000 after buying an additional 5,686 shares in the last quarter.

Insmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company’s lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.